BeiGene Invests US$800 million to Construct New R & D facility in China
Introduction:
BeiGene is investing US$800 million in constructing a new research and development (R&D) facility in China.
Features:
The new facility features state-of-the-art biologics manufacturing capabilities along with a clinical research and development centre.
With approximately 400,000 square feet dedicated to commercial-stage biologic pharmaceutical manufacturing, the site has room for future expansion. It also enhances late-stage research and clinical development, driving the rapid ascent to global oncology leadership.
Building on existing capabilities, the facility supports large-scale production, reducing costs, ensuring supply chain resiliency, avoiding global disruptions, protecting capacity, and quickly adapting to the latest innovative modalities.
The opening of this campus underscores a commitment to fostering innovation and creating high-tech jobs in the Garden State by the end of 2025.
Specifications:
| Name | BeiGene |
| Type | New Construction |
| Budget | US$800 million |
| Year | 2025 |
